Speakers 2020
-
New drugs for HDV
Presentation
-
-
NAFLD/NASH - Session 2: the arrival of treatments (chairman)
Presentation
-
-
(chairman)
Presentation
-
-
New endpoints and biomarkers for treatment of CHB
-
(chairman)
Presentation
-
-
(chairman)
-
Cholestatic liver diseases and cholangiocarcinoma
Presentation
-
-
(chairman)
Presentation
-
-
TAKE HOME MESSAGES
-
(chairman)
Presentation
-
-
Current pharmacological treatments for NASH
Presentation
-
-
Optimal management of CHB patients under NUC
-
(chairman)
Presentation
-
-
(chairman)
-
Non invasive markers in NAFLD
Presentation
-
-
New EASL Recommendations for the management of occupational liver disease
-
HEPATOCELLULAR CARCINOMA (chairman)
Presentation
-
-
HEPATITIS C: the elimination (chairman)
Presentation
-
-
NASH: the vision of the diabetologist
Presentation
-
-
(chairman)
Presentation
-
-
END STAGE LIVER DISEASE (chairman)
-
Acute on chronic liver failure
Presentation
-
DUSHEIKO Geoffrey
UK
-
HEPATITIS B - SESSION 2: therapy of hepatitis B tomorrow: HBV cure (chairman)
-
Will we need novel combinations to cure HBV infection?
Presentation
-
-
HEPATITIS B - SESSION 1: therapy of hepatitis B today: HBV suppression (chairman)
Presentation
-
FERRARI Carlo
Italy
-
Boosting innate and adaptive immunity for HBV cure
Presentation
-
-
(chairman)
Presentation
-
-
HEPATITIS C: the elimination (chairman)
-
TAKE HOME MESSAGES
Presentation
-
-
(chairman)
-
What’s new in portal hypertension?
Presentation
-
-
HEPATOCELLULAR CARCINOMA (chairman)
Presentation
-
-
(chairman)
Presentation
-
-
HEPATITIS B - SESSION 2: therapy of hepatitis B tomorrow: HBV cure (chairman)
Presentation
-
LIM Seng Gee
Singapore
-
HEPATITIS B - SESSION 1: therapy of hepatitis B today: HBV suppression (chairman)
-
Who to treat? A critical review of the international guidelines
-
(chairman)
Presentation
-
-
(chairman)
Presentation
-
MANNS Michael
Germany
-
The future of autoimmune liver diseases
Presentation
-
-
INTRODUCTION
-
Award PHC 2020 (chairman)
-
CONCLUSION
-
INTRODUCTION
-
CONCLUSION
Presentation
-
-
(chairman)
-
Optimal management of HCC today
Presentation
-
NEGRO Francesco
Switzerland
-
NAFLD/NASH - Session 1: a step forward a better understanding (chairman)
-
Natural history of NASH and HCC
Presentation
-
-
HEPATITIS DELTA (chairman)
-
New epidemiology of hepatitis delta
Presentation
-
-
Improving histological score for NASH
Presentation
-
-
How to optimize current therapy with PEG IFN?
Presentation
-
-
Hepatitis E: what is the real issue?
-
(chairman)
Presentation
-
PINZANI Massimo
UK
-
Physiopathology of NAFLD and NASH
Presentation
-
-
Micro elimination
Presentation
-
RAUTOU Pierre-Emmanuel
France
-
(chairman)
Presentation
-
-
HEPATITIS DELTA (chairman)
Presentation
-
-
Nutrition and NASH
Presentation
-
-
END STAGE LIVER DISEASE (chairman)
Presentation
-
SANGRO Bruno
Spain
-
(chairman)
-
Immunotherapy for HCC: when and how
Presentation
-
-
(chairman)
-
NAFLD/NASH - Session 2: the arrival of treatments (chairman)
-
Current management of NASH
Presentation
-
-
NAFLD/NASH - Session 1: a step forward a better understanding (chairman)
-
(chairman)
Presentation
-
-
Approach to the patient with CHB and decompensated cirrhosis
Presentation
-
-
Liver transplantation for HCC
Presentation
-
THABUT Dominique
France
-
Optimal management of ascitis
Presentation
-
-
(chairman)
Presentation
-
VALLA Dominique
France
-
Vascular liver disease: new advances
Presentation
-
VILGRAIN Valérie
France
-
Advances in imagery for liver tumors
Presentation
-
WEDEMEYER Heiner
Germany
-
*Workshop supported by an unrestricted educational grant from MYR Pharmaceuticals (chairman)
Presentation
-
WEILAND Ola
Sweden
-
Macro elimination
Presentation
-
ZEUZEM Stefan
Germany
-
The last difficult to treat patients
Presentation
-
ZOULIM Fabien
France
-
Can we cure HBV with novel direct acting antivirals?
-
*Workshop supported by an unrestricted educational grant from MYR Pharmaceuticals (chairman)
Presentation
-